Silence TherapeuticsSLN -4.28%45 Net Current Asset Value is $0.79 as of Mar. 2026, which is 89% below its 10-year median of 7.22. GuruFocus rates SLN with a GF Score™ of 45/100 and a GF Value™ of $0.25 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 946 Biotechnology companies, Silence Therapeutics ranks worse than 68.29% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Silence Therapeutics's net current asset value per share for the quarter that ended in Mar. 2026 was $0.79.
The historical rank and industry rank for Silence Therapeutics's Net Current Asset Value or its related term are showing as below:
SLN'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.38 Med: 7.22 Max: 72.5
Current: 8.07
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Silence Therapeutics was 72.50. The lowest was 1.38. And the median was 7.22.
SLN's Price-to-Net-Current-Asset-Value is ranked worse than 68.29% of 946
companies
in the Biotechnology industry
Industry Median: 4.87
vs SLN: 8.07
Silence Therapeutics (NAS:SLN) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Silence Therapeutics Net Current Asset Value Related Terms
Silence Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Silence Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silence Therapeutics Net Current Asset Value Chart
SLN vs IMRX, VRXA, MGNX: Net Current Asset Value Comparison
For the Biotechnology subindustry, Silence Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silence Therapeutics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Silence Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.79 mean?
Silence Therapeutics (SLN) has a Net Current Asset Value of $0.79 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Silence Therapeutics and its competitors. This is 89% below median its historical median of 7.22. Over the past decade, Silence Therapeutics' Net Current Asset Value has ranged from 1.38 to 72.50. According to the industry distribution chart, Silence Therapeutics ranks #646 out of 946 companies in the Biotechnology industry, placing it in the top 68.3%.
Is Silence Therapeutics' Net Current Asset Value too high?
Silence Therapeutics' current Net Current Asset Value of $0.79 is 89% below median its 10-year median of 7.22. Over the past 10 years, this metric has ranged from a low of 1.38 to a high of 72.50. The Biotechnology industry median Net Current Asset Value is 4.87. Silence Therapeutics' value of $0.79 is 83.8% below this industry median. Based on the distribution chart, Silence Therapeutics ranks #646 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Silence Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Net Current Asset Value compare to IMRX and VRXA?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #646 out of 946 companies for Net Current Asset Value. This places Silence Therapeutics in the lower half of its industry. The industry median Net Current Asset Value is 4.87. Silence Therapeutics' value of $0.79 is 83.8% below this benchmark. Historically, Silence Therapeutics' own Net Current Asset Value has ranged from 1.38 to 72.50 over the past decade. While the company's 10-year median is 7.22 vs. the industry median of 4.87, Silence Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.87, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Silence Therapeutics's current Net Current Asset Value of $0.79 is 83.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Silence Therapeutics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Silence Therapeutics's current Net Current Asset Value is $0.79, which is 89% below median its own 10-year median of 7.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.25, compared to a current price of $10.49 — trading 4096% above its estimated fair value. The current Net Current Asset Value is $0.79, which is 89% below median its 10-year median of 7.22 and 83.8% below the Biotechnology industry median of 4.87. Silence Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Net Current Asset Value is $0.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Silence Therapeutics (SLN) Overvalued in 2026?
Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued.
The current stock price of $10.49 is trading 4096% above its estimated GF Value™ of $0.25.
GuruFocus considers Silence Therapeutics to be Significantly Overvalued.
Key valuation signals for SLN:
Net Current Asset Value: $0.79 (89% below median its 10-year median of 7.22)
GF Value™: $0.25 vs. price of $10.49 (4096% above fair value)
Industry Position: 83.8% below the Biotechnology median (#646 of 946)
No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
45GF Score
Get the complete analysis for SLN
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLN has been successfully added to your 
